Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients | Zendy

F. Estevinho | Zendy; Rita Gomes | Zendy; Direndra Hasmucrai | Zendy; Fernando Barata | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients

Author(s) -

F. Estevinho,

Rita Gomes,

Direndra Hasmucrai,

Fernando Barata

Publication year - 2020

Publication title -

pulmonology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.826

H-Index - 22

eISSN - 2531-0437

pISSN - 2531-0429

DOI - 10.1016/j.pulmoe.2020.09.003

Subject(s) - medicine , vinorelbine , discontinuation , lung cancer , adverse effect , oncology , population , cancer , gastroenterology , chemotherapy , environmental health , cisplatin

An increasing body of evidence from clinical trials and real-world studies suggests that metronomic oral vinorelbine (VNR) is a promising treatment option for elderly and unfit advanced non-small cell lung cancer (NSCLC) patients. The aim of this multicenter study was to present real-world data about the experience in treatment of NSCLC with metronomic VNR in Portugal.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research